The company maintains the Cor.At offering will complement its existing Clonetics® and Poietics® families of primary cells and optimized media. “The Axiogenesis portfolio is an ideal fit with Lonza’s activities and strengthens the research solutions’ product and service offering, especially in the field of drug discovery,” states Tuen van der Heide, Ph.D., head of research solutions for Lonza’s bioscience business.

Axiogenesis specializes in the development of novel assays based on in vitro differentiated murine embryonic stem cells or human and murine induced pluripotent stem cells. The company’s Cor.At cardiomyocytes have been used to generate an assay for predicting cardiac cytotoxicity in drug candidates and for HTS. The Cor.At cells also form the basis of what Axiogenesis claims is the first physiologically relevant disease model of cardiomyopathy. Both types of in vitro assays are offered as a kit or a service. The firm is also working to develop new test systems utilizing ESC-derived hepatocyte, endothelial, neuronal, and dermal cells.

Axiogenesis currently has over 25 individual stem cell lines along with protocols for their cultivation into more than 15 different tissues.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

56.6%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.